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Objectives. To determine whether early administration of cap-
topril lessens infarct zone regional wall motion abnormalities
when infarct artery blood flow is abnormal.
Background. The interaction between angiotensin-converting
enzyme (ACE) inhibitor therapy, ventricular function and infarct
artery blood flow has not been well described.
Methods. A total of 493 patients aged <275 years with first
infarctions, presenting within 4 h of symptom onset, were ran-
domized to receive 6.25 mg captopril, increasing to 50 mg t.d.s. or
a matching placebo 2.1 6 0.4 h after commencing intravenous
streptokinase (1.5 3 106 U over 30 to 60 min). Trial therapy was
stopped 48 h prior to angiography at 3 weeks, to determine
regional wall motion and infarct artery flow.
Results. There were no differences in ejection fractions or
end-systolic volumes between patients randomized to receive
captopril and those randomized to receive a placebo. Among
patients with anterior infarction (n 5 216), randomization to
captopril resulted in fewer hypokinetic chords (40 6 13; vs. 44 6
13; p 5 0.028) and a trend toward fewer chords >2 SD below
normal (26 6 17 vs. 30 6 17; p 5 0.052) in the infarct zone. In
patients randomized to receive captopril who had anterior infarc-
tion and Thrombolysis in Myocardial Infarction (TIMI) 0–2, flow
there were fewer hypokinetic chords (44 6 12 vs. 50 6 9; p 5
0.043) and a trend toward fewer chords >2 SD below normal
(33 6 15 vs. 39 6 13; p 5 0.057). Patients receiving captopril who
had anterior infarction and corrected TIMI frame counts >27 had
fewer hypokinetic chords (42 6 13 vs. 46 6 12; p 5 0.015) and
fewer chords >2 SD below normal (27 6 17 vs. 32 6 17; p 5
0.047). Captopril had no effect in patients with inferior infarction.
There were 20 late cardiac deaths (median follow-up 4 years) in
the captopril group and 35 in the placebo group (p 5 0.036).
Conclusions. Randomization to receive captopril 2 h after
streptokinase improved regional wall motion at 3 weeks. The
greatest benefit was seen in patients with anterior infarction
particularly when infarct artery blood flow is reduced.
(J Am Coll Cardiol 1999;33:139–45)
©1998 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitor trials after
myocardial infarction (MI) have randomized almost 100,000
patients within 24 h of symptom onset (1–4). At 5 weeks
approximately five lives per 1,000 were saved in patients
randomized to receive ACE inhibitors (1–3), with almost half
the mortality benefit occurring on days 0 to 1 (5,6). Patients
with anterior infarction have twice as much benefit (5,6).
Left ventricular dilatation (7) is a major determinant of
increased mortality after acute MI, and is decreased by ACE
inhibitors (8–11). Both left ventricular function and infarct-
related artery patency independently influence long-term prog-
nosis (12), with patency being a major determinant of left
ventricular function and dilatation (12). However, there are
limited data on the interaction of this relationship with ACE
inhibition (13).
To examine the influence of early ACE inhibition on
ventricular function and infarct artery blood flow, we random-
ized patients to receive captopril 2 h after streptokinase. We
hypothesized that the major effect of captopril would occur in
patients with anterior infarction and abnormal infarct artery
flow.
Methods
Study population. From April 24, 1989, through December
7, 1994, patients aged #75 years presenting within 4 h of the
onset of $30 min chest pain and with $1 mm of ST-segment
elevation in two contiguous electrocardiographic leads, or
$2 mm in leads V1–V3 (14), were evaluated for enrollment. In
addition to our previously reported contraindications against
streptokinase (14,15), patients with prior MI who were receiv-
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ing an ACE inhibitor and those with systolic blood pressure
(BP) of ,90 mm Hg 6 h after thrombolysis were excluded.
Patients were given oral aspirin (300 mg), intravenous
streptokinase (1.5 3 106 U over 30 to 60 min) and heparin
(5,000 U were administered followed by a 48-h infusion of
1,000 U/h, adjusted to maintain the activated partial thrombo-
plastin time between 90 and 110 s). Randomization to receive
6.25 mg captopril or matching placebo occurred 2 h after
streptokinase was commenced if the systolic BP was
$90 mm Hg. Dosing was increased, starting 2 h after random-
ization, as follows: 12.5 mg (3 doses), 25 mg (3 doses), then
50 mg 3 times daily for 3 weeks. Doses were lowered or omitted
for hypotension. Trial therapy was stopped 48 h prior to
angiography. Therapy, including ACE inhibitors, was at the
physician’s discretion following angiography.
Beta-blocker therapy was continued or commenced on days
2 to 3 in patients without contraindications. Reinfarction was
defined as 20 min of chest pain and elevation of creatine kinase
above twice normal and/or the development of new Q waves
($4 mV). Exercise testing (Bruce protocol) was performed at
3 weeks, unless contraindicated.
The primary end point was the effect of captopril on
regional wall motion in the “area at risk” in the infarct zone in
patients with anterior infarction. We also examined the inter-
action among therapy, infarct-related artery blood flow and
ventricular function. Other secondary end points included the
effects of captopril on inferior infarction, on ventricular vol-
umes, on the ejection fraction, and on cardiac mortality (16).
The adverse effects of captopril on blood pressure and renal
function, and the occurrence of cardiogenic shock, were mon-
itored.
Angiographic analysis. Angiography was scheduled 3
weeks after infarction unless medically uncontrolled ischemia
mandated earlier investigation (see Fig. 1). Revascularization
was performed either for ischemia refractory to medical ther-
apy or for $50% left main coronary stenosis.
Angiography was performed as previously described (15).
Angiographic parameters were assessed blind to treatment
allocation and patient outcome. The infarct-related artery was
identified by either the site of electrocardiographic ST-
segment changes, regional wall-motion abnormalities on ven-
triculography, or the presence of thrombus. Infarct-related
artery flow was classified according to the Thrombolysis in
Myocardial Infarction (TIMI) flow grade (17) and the cor-
rected TIMI frame count, with normal described as #27
(mean 6 2 SD of individuals without infarction) (18). Ventric-
ular volumes and the ejection fraction were calculated by an
integration method, and regional wall motion was assessed by
quantitative angiographic chord scores using a modification of
the centerline method from the right anterior oblique ventricu-
logram (19). In this projection the “area at risk” or infarct zone
for chord motion analysis was defined by the culprit lesion and
the most distal landmark of the infarct-related artery (exclud-
ing nondominant left circumflex arteries, which were not
profiled). Regional wall motion was analyzed with respect to
the number of hypokinetic chords (below mean normal wall
motion); the number of chords .1 SD and .2 SD below
normal wall motion; the sum of hypokinetic chords (number of
hypokinetic chords 3 SD from normal); and mean hyperki-
netic chords in the noninfarct-zone (19).
Statistical analysis. To determine the effect of captopril in
anterior infarction—the primary end point—the estimated
sample size was 218 (a 5 0.80, b 5 0.05; two-tailed). A 20%
difference between captopril and placebo in the number of
hypokinetic chords .2 SD below normal mean motion in the
infarct zone was hypothesized (19). Assuming that approxi-
mately 50% of patients had anterior infarction, and that 15%
would not have ventriculograms suitable for analysis, the
estimated total number of patients required was 510.
Analyses were performed on an intention-to-treat basis,
with data expressed as mean 6 SD. Kaplan-Meier survival
curves were compared by log-rank tests. Continuous variables
were compared by unpaired t tests. Multivariate logistic regres-
sion analyses were performed. For multiple comparisons, a
one-way analysis of variance (ANOVA), with post hoc analysis
by the Student-Newman-Keuls test, was performed.
Results
Intravenous streptokinase was administered to 512 patients
3.1 6 1.4 h after symptom onset (Fig. 1). Randomization was
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
TIMI 5 Thrombolysis in Myocardial Infarction
MI 5 myocardial infarction
Figure 1. Flow diagram.
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precluded in 13 patients because of persistent hypotension at
6 h; in 3 patients due to previous ACE inhibitor therapy, and
in 3 because age and/or electrocardiographic (ECG) entry
criteria were not fulfilled. Patients were administered either
captopril (243 patients) or placebo (250 patients) 2.1 6 0.4 h
after commencing streptokinase (for baseline characteristics,
see Table 1). Ventriculography was performed at 22 6 6 days
in 432 (88%) patients. The reasons for not performing ven-
triculography included 16 deaths, 6 previous MI (identified
retrospectively), 9 coronary angiography only, and 30 patients
declined (Fig. 1).
Clinical outcome. At 30 days, mortality (Table 2) was 2%
in the captopril group and 4.8% in the placebo group (p 5
0.078). Revascularization was performed in 18 patients (2 with
left main stenosis) in the captopril group and 16 (3 with left
main stenosis) in the placebo group. Reinfarction occurred in
13 and 17 patients randomized to receive captopril and pla-
cebo, respectively.
Over a median follow-up of 4 years (interquartile range 2.7
to 5.1 years) there were 20 cardiac deaths (11 with anterior MI)
and 5 noncardiac deaths in the captopril group and 35 cardiac
deaths (22 with anterior MI) and 10 noncardiac deaths in the
placebo group (p 5 0.036) (Fig. 2). The ACE inhibitors were
prescribed to 32% of surviving patients in each group
(Table 3).
Left ventricular function. Indices of left ventricular func-
tion including the ejection fraction, end-systolic volume and
end-diastolic volume were similar in each group (Table 4). No
differences existed between treatment groups whether arteries
were patent (TIMI 2–3) or occluded (TIMI 0–1). Six patients
had ventriculograms unsuitable for regional wall-motion anal-
ysis because of poor opacification or ventricular ectopy, and 18
patients had nondominant left circumflex infarct arteries
(Fig. 1).
Regional wall motion and TIMI flow grades. Patients with
anterior infarction in the captopril group had fewer hypoki-
netic chords, chords .1 SD and .2 SD below normal, and a
smaller sum of hypokinetic chords compared with the placebo
group (all p # 0.05). Patients with anterior infarction and
TIMI 0–2 flow in the captopril group had fewer hypokinetic
chords (44 6 12) compared with the placebo group (50 6 9;
p 5 0.043), and a trend toward fewer chords .2 SD below
normal (33 6 15 vs. 39 6 13; p 5 0.057). The number of
Figure 2. Cardiac mortality according to treatment randomization.
Log-rank comparisons of cardiac mortality in the captopril (243) and
placebo (250) groups at 1, 3 and 5 years were p 5 0.044, p 5 0.045 and
p 5 0.063, respectively. At these follow-up times the number of
patients were 435, 332 and 122, respectively.
Table 1. Baseline Patient Characteristics
All Patients
Patients With Regional
Wall-Motion Analysis
Captopril
(n 5 243)
Placebo
(n 5 250)
Captopril
(n 5 204)
Placebo
(n 5 204)
Age (yr) 58 6 10 59 6 10 57 6 10 59 6 9
Male 191 (79%) 194 (78%) 162 (79%) 165 (81%)
Hypertension 60 (25%) 71 (28%) 49 (24%) 55 (27%)
Diabetes 19 (8%) 16 (6%) 14 (7%) 12 (6%)
Smoker 103 (42%) 91 (36%) 87 (43%) 79 (39%)
Angina (.3 months) 75 (31%) 71 (28%) 62 (30%) 53 (26%)
Beta-blockers 28 (11.5%) 35 (14%) 20 (10%) 26 (13%)
Previous CABG/PTCA 0/0 3/1 0/0 1/1
Anterior infarction 117 † (48%) 120 (48%) 110 † (54%) 106 (52%)
Time to streptokinase* (h) 2.9 6 1.3 3.1 6 1.3 2.9 6 1.3 3.1 6 1.3
Time to captopril‡ (h) 2.1 6 0.44 2.2 6 0.50 2.1 6 0.45 2.2 6 0.48
*Time to streptokinase from symptom onset. †One patient had both anterior and inferior infarctions. ‡Time to first
captopril dose after starting streptokinase. CABG, Coronary Artery Bypass Grafting; PTCA, Percutaneous Transluminal
Coronary Angioplasty.
Table 2. Causes of 30-Day Mortality
Captopril* Placebo†
Heart failure/shock 4 5
Sudden death/ventricular fibrillation 0 1
Cardiac rupture 1 3
Reinfarction 0 2
*3 anterior infarction. †10 anterior infarction.
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patients with either anterior or inferior infarction and occluded
infarct arteries (TIMI 0–1 flow) was similar in each treatment
group, and there were no significant treatment effects on
regional wall motion (Table 5).
Regional wall motion and corrected TIMI frame counts. In
patients with anterior infarction and corrected TIMI frame
counts of .27, the number of hypokinetic chords in the
captopril group was 42 6 13 compared with 46 6 12 in the
placebo group (p 5 0.015), and the number of chords .2 SD
below normal was 27 6 17 compared with 32 6 17 in the
placebo group (p 5 0.047) (Table 6, Fig. 3). Captopril had no
effect when corrected TIMI frame counts were ,27.
In patients with patent infarct-related arteries there was a
relationship between the corrected TIMI frame count exam-
ined as a continuous variable and both the number of hypoki-
netic chords (r 5 .19; p , 0.001) and the number of hypoki-
netic chords .2 SD below normal (r 5 .21; p , 0.001).
Adverse effects. In the first 24 h, systolic blood pressure
#90 mm Hg occurred in 87 patients in the captopril group and
58 in the placebo group (p 5 0.003). No differences were seen
in the frequency of death from cardiogenic shock (Table 2).
Randomized therapy of 150 mg daily was not achieved in 17%
of patients in the captopril group (mean dose 120 6 53 mg)
and in 11% of patients in the placebo group.
Predictors of late cardiac death. Univariate predictors of
late cardiac death were: age (x2 5 19.2; p 5 0.0001); ejection
fraction (x2 5 14.1; p , 0.0001); end-systolic volume (x2 5
11.6; p 5 0.0006); chords .2 SD below normal (x2 5 10.9; p 5
0.001); exercise time (x2 5 8.69; p 5 0.003); and randomiza-
tion to receive captopril (x2 5 4.44; p 5 0.035). Significant
predictors on multivariate analysis were age and either the
number of chords .2 SD below normal or the ejection fraction
or the end-systolic volume (all p , 0.001).
Discussion
We found that regional wall-motion abnormalities in the
infarct zone were less in patients with anterior infarction who
were randomized to receive captopril, compared with placebo,
starting 2 h after the commencement of streptokinase therapy.
The major benefit occurred in patients with anterior infarction
and either TIMI 0–2 flow or a corrected TIMI frame count
.27.
Randomized trials of early ACE inhibition after infarction
(8–10,20–23) show that the mortality benefit appears within
24 h (5). This benefit on days 0 to 1 constituted 31% of the
total survival benefit at 35 days in the Fourth International
Studies of Infarct Survival (2) and 28% in the Gruppo Italiano
per lo Studio della Sopravvivenza nell’Infarto Miocardico–3
(GISSI-3) (1).
Left ventricular function. The major predictor of survival
after MI is left ventricular function (24,25), and end-systolic
volume is a more powerful predictor than ejection fraction (7).
Patency of the infarct-related artery has a major effect on left
ventricular dilatation (23,26). Blood in patent infarct arteries
and coronary veins helps provide a scaffold to limit dilatation
(22,27,28). ACE inhibition after MI attenuates left ventricular
dilatation, which commences within the first few hours after
the onset of coronary occlusion (5,8,11,21,29–31).
Factors affecting the degree of ventricular remodeling and
dilatation include the size and site of the infarct (anterior
infarcts remodel more). Thrombolytic therapy reduces left
ventricular dilatation (15), and the effect of ACE inhibitor
therapy may be greater in patients who do not achieve normal
infarct artery reperfusion and in those who do not fulfill
criteria for reperfusion therapies.
The effects on left ventricular function of randomization to
receive an ACE inhibitor therapy within 24 h of thrombolysis
Table 3. Medication at Follow-up
Captopril
(n 5 195)
Placebo
(n 5 194)
ACE inhibitors 32% 32%
Beta-blocker 52% 40%
Aspirin 88% 89%
Lipid modifying therapy 36% 34%
LIPID study* 15% 16%
Long-acting nitrates 27% 21%
Digoxin 4% 4%
Diuretics 11% 16%
Calcium antagonists 23% 17%
Data available for 95% of survivors. *Patients in the Long-Term Intervention
with Pravastatin in Ischemic Disease (LIPID study were randomized to receive
either pravastatin or a placebo (see Ref 16).
Table 4. Effect of Captopril on Left Ventricular Function According to TIMI Flow Grades
TIMI 3 TIMI 0–2
Captopril Placebo p Captopril Placebo p
Anterior infarction (n 5 81) (n 5 72) (n 5 29) (n 5 34)
Ejection fraction (%) 57.9 6 13.4 57.4 6 15.1 0.99 50.3 6 16.4 48.7 6 13.3 0.56
End-systolic volume (ml) 64 6 36 65 6 35 0.96 95 6 65 101 6 54 0.72
End-diastolic volume (ml) 147 6 49 148 6 48 0.83 178 6 87 188 6 64 0.71
Inferior infarction (n 5 59) (n 5 62) (n 5 47) (n 5 48)
Ejection fraction (%) 63.8 6 12.1 61.0 6 10.5 0.40 57.0 6 10.4 57.0 6 8.3 0.78
End-systolic volume (ml) 58 6 32 55 6 29 0.33 66 6 36 65 6 23 0.85
End-diastolic volume (ml) 153 6 55 133 6 41 0.02 149 6 60 147 6 42 0.89
TIMI 5 thrombolysis in myocardial infarction.
142 FRENCH ET AL. JACC Vol. 33, No. 1
CAPTOPRIL DECREASES ANTERIOR REGIONAL WALL MOTION ABNORMALITIES January 1999:139–45
or angioplasty treatments for anterior MI have been examined
in two randomized trials (32,33). In the Captopril and Throm-
bolysis Study (33) no changes in ventricular volumes, assessed
by 2-D echocardiography, were found over 1 year in 298
patients receiving captopril (25 mg 3 times daily), compared
with placebo, beginning 3.5 h after treatment with streptoki-
nase (in comparison with 2.1 h in our study). The Healing and
Early Afterload Reducing Therapy trial (32) performed 2-D
echocardiography from days 1 to 14 following reperfusion
therapy (77% thrombolysis, 23% primary angioplasty). Pa-
tients were randomized on day 1 (for 14 days) to receive 1)
placebo (delayed) or 2) ramipril 0.625 mg daily (low) or 3)
Table 5. Effect of Captopril on Regional Wall Motion According to TIMI Flow Grade
Anterior Inferior
All TIMI Grades Captopril (110) Placebo (106) p Captopril (94) Placebo (98) p
Sum of hypokinetic chords 98 6 56 114 6 56 0.038 49 6 35 50 6 28 0.88
Hypokinetic chords 40 6 13 44 6 13 0.028 29 6 12 29 6 10 0.91
Chords .1 SD* 34 6 17 39 6 17 0.041 20 6 12 21 6 11 0.56
Chords .2 SD* 26 6 17 30 6 17 0.052 11 6 10 12 6 10 0.46
Mean hyperkinetic chords 0.71 6 0.62 0.84 6 0.69 0.15 0.87 6 0.71 0.69 6 0.54 0.054
TIMI 3 Captopril (81) Placebo (71) p Captopril (53) Placebo (53) p
Sum of hypokinetic chords 88 6 54 99 6 56 0.23 41 6 33 41 6 28 0.97
Hypokinetic chords 39 6 13 42 6 14 0.22 27 6 13 27 6 11 0.97
Chords .1 SD* 32 6 17 35 6 18 0.26 17 6 12 18 6 12 0.84
Chords .2 SD* 22 6 17 25 6 17 0.38 8 6 9 8 6 10 0.93
Mean hyperkinetic chords 0.65 6 0.55 0.85 6 0.74 0.06 0.86 6 0.65 0.71 6 0.53 0.20
TIMI 0–2 Captopril (29) Placebo (35) p Captopril (41) Placebo (45) p
Sum of hypokinetic chords 126 6 53 144 6 42 0.12 59 6 36 60 6 24 0.89
Hypokinetic chords 44 6 12 50 6 9 0.043 31 6 10 31 6 7.8 0.97
Chords .1 SD* 44 6 14 47 6 10 0.060 23 6 12 25 6 8.8 0.55
Chords .2 SD* 33 6 15 39 6 13 0.057 14 6 11 15 6 8.8 0.38
Mean hyperkinetic chords 0.89 6 0.78 0.82 6 0.60 0.71 0.88 6 0.78 0.68 6 0.56 0.16
TIMI 0–1 Captopril (22) Placebo (15) p Captopril (30) Placebo (37) p
Sum of hypokinetic chords 131 6 52 145 6 44 0.38 60 6 35 60 6 25 0.95
Hypokinetic chords 46 6 10 50 6 9 0.24 31 6 9 31 6 8 0.77
Chords .1 SD* 44 6 13 48 6 11 0.3 24 6 10 25 6 9 0.64
Chords .2 SD* 35 6 15 40 6 12 0.22 14 6 10 15 6 9 0.48
Mean hyperkinetic chords 0.77 6 0.77 0.81 6 0.71 0.87 0.92 6 0.75 0.73 6 0.58 0.26
TIMI 2 Captopril (7) Placebo (20) p Captopril (11) Placebo (8) p
Sum of hypokinetic chords 109 6 56 144 6 42 0.18 54 6 40 58 6 22 0.80
Hypokinetic chords 38 6 15 49 6 9 0.10 30 6 14 33 6 9 0.59
Chords .1 SD* 34 6 17 47 6 9 0.10 23 6 16 25 6 11 0.75
Chords .2 SD* 28 6 16 40 6 13 0.13 13 6 14 16 6 8 0.63
Mean hyperkinetic chords 1.24 6 0.77 0.83 6 0.52 0.23 0.79 6 0.89 0.43 6 0.37 0.25
*Represents .1 or .2 SD below normal wall motion. TIMI 5 thrombolysis in myocardial infarction.
Table 6. Effect of Captopril on Regional Wall Motion According to Corrected TIMI Frame Count
Anterior Inferior
CTFC.27 Captopril (89) Placebo (87) p Captopril (73) Placebo (79) p
Sum of hypokinetic chords 103 6 56 120 6 54 0.039 52 6 37 50 6 26 0.76
Hypokinetic chords 42 6 13 46 6 12 0.015 30 6 11 29 6 8.9 0.65
Chords .1 SD* 36 6 16 41 6 16 0.042 21 6 12 21 6 11 0.86
Chords .2 SD* 27 6 17 32 6 17 0.047 11 6 11 12 6 9.6 0.61
Mean hyperkinetic chords 0.68 6 0.63 0.86 6 0.71 0.076 0.83 6 0.72 0.70 6 0.55 0.18
CTFC#27 Captopril (21) Placebo (19) p Captopril (21) Placebo (19) p
Sum of hypokinetic chords 77 6 51 85 6 61 0.65 39 6 29 47 6 34 0.42
Hypokinetic chords 36 6 13 36 6 14 0.95 26 6 13 29 6 13 0.41
Chords .1 SD* 27 6 16 30 6 18 0.62 16 6 12 19 6 13 0.46
Chords .2 SD* 19 6 15 20 6 17 0.77 8.9 6 9.7 11 6 12 0.61
Mean hyperkinetic chords 0.85 6 0.59 0.77 6 0.62 0.65 0.99 6 0.65 0.69 6 0.51 0.12
*.1 or .2 SD below normal wall motion. CTFC 5 corrected TIMI frame count.
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ramipril 1.25 mg increasing to 10 mg daily (early). Patients
randomized to the highest ramipril dose showed the greatest
improvement in ejection fraction compared with early, low,
and delayed ramipril (4.9 6 10.0% vs. 3.9 6 8.2% vs. 2.4 6
8.8%; p , 0.05). These studies (32,33) did not examine the
effects of infarct artery blood flow on ventricular function.
Our study determined regional wall motion in the infarct
zone, allowing examination of treatment effects with fewer
ventriculograms (19), and was not powered to determine the
effects of captopril on the ejection fraction, end-systolic, or
end-diastolic volumes. The reduction of abnormal chord mo-
tion was approximately 15% at 3 weeks in patients with
anterior infarction who were randomized to receive captopril.
Because not all patients had ventriculograms, it is possible that
the effects on ventricular function which we observed may have
been greater in the initial hours and days after infarction
affecting early survival.
Infarct-related artery flow. Patients with anterior infarc-
tion and TIMI 0–2 flow, or corrected TIMI frame counts of
.27, who were randomized to receive captopril had fewer wall
motion abnormalities compared with the patients randomized
to placebo. There was a correlation between the corrected
TIMI frame count, assessed as a continuous variable, and the
number of hypokinetic chords .2 SD below normal (p ,
0.001), albeit relatively weak (r 5 .21). Corrected TIMI frame
counts have been shown to be a more reproducible measure-
ment of infarct artery flow than TIMI flow grades (18). The
differences in assessments of the effects of captopril on infarct
zone regional wall motion with respect to infarct artery blood
flow were modest when corrected TIMI frame counting was
compared with TIMI flow grading (Tables 5 and 6).
One other study has examined the effect of infarct artery
flow, ACE inhibition and outcome (13). The Survival and
Ventricular Enlargement investigators (13) showed that pa-
tients (44% received thrombolysis) with occluded arteries who
were randomized to receive captopril 3 to 16 days after MI had
a reduction in a composite end point that included late
mortality, decreased ventricular function and hospitalization.
Captopril had no effect in patients with patent arteries.
The limitations of our study include the assessment of
infarct artery coronary blood flow at 3 weeks, which represents
the net effects of early and late reperfusion and reocclusion.
The effect of captopril on anterior regional wall motion may
have been different had it been examined with respect to
90-min infarct artery flow. Also, we did not have a prospective
screening log.
We randomized a low-risk population and we cannot
extrapolate our data to patients either $76 years or to those
treated with other thrombolytic regimens. Late cardiac death
was reduced (p 5 0.036) in patients randomized to receive
captopril, but our study was not powered for mortality and
patients received randomized therapy for only 3 weeks. Late
ACE inhibitor therapy was prescribed to 32% of patients in
each group (Table 3), and was unlikely to have influenced
differences in late survival.
Conclusions. Patients with anterior infarction benefit from
very early administration of ACE inhibitor therapy, particu-
larly when the infarct artery blood flow is abnormal. Whether
long-term ACE inhibitor therapy is required when impaired
infarct artery blood flow is improved by percutaneous or
surgical revascularization is unknown.
Figure 3. Effect of captopril on regional wall motion in anterior
infarction according to corrected TIMI frame counts. (A) Number of
abnormal chords; (B) number of chords .2 SD below normal; (C)
total hypokinetic chords. Only the comparisons indicated were signif-
icant.
144 FRENCH ET AL. JACC Vol. 33, No. 1
CAPTOPRIL DECREASES ANTERIOR REGIONAL WALL MOTION ABNORMALITIES January 1999:139–45
The secretarial assistance of Clarissa Gould-Thorpe and the statistical advice of
Heather Smith is gratefully acknowledged. Grant support was obtained from the
Health Research Council of New Zealand and the National Heart Foundation of
New Zealand.
References
1. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.
GISSI–3: effects of lisinopril and transdermal glyceryl trinitrate singly and
together on 6-week mortality and ventricular function after acute myocardial
infarction. Lancet 1994;343:1115–22.
2. Fourth International Study of Infarct Survival Collaborative Group. ISIS–4:
a randomised factorial trial assessing early oral captopril, oral mononitrate,
and intravenous magnesium sulphate in 58,050 patients with suspected acute
myocardial infarction. Lancet 1995;345:669–85.
3. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo
among 13,634 patients with suspected acute myocardial infarction: interim
report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686–7.
4. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-
converting-enzyme inhibitor zofenopril on mortality and morbidity after
anterior myocardial infarction: the Survival of Myocardial Infarction Long-
Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:
80–5.
5. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for
ACE inhibitors in the early treatment of acute myocardial infarction:
systematic overview of individual data from 100,000 patients in randomized
trials. Circulation 1998;97:2202–12.
6. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G, for the Meeting
Participants. ACE inhibitor use in patients with myocardial infarction:
summary of evidence from clinical trials. Circulation 1995;92:3132–7.
7. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ.
Left ventricular end-systolic volume as the major determinant of survival
after recovery from myocardial infarction. Circulation 1987;76:44–51.
8. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of
captopril on progressive ventricular dilatation after anterior myocardial
infarction. N Engl J Med 1988;319:80–6.
9. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy
on the infarcted left ventricle of the rat. Circ Res 1985;57:84–95.
10. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental
myocardial infarction: beneficial effects of long-term therapy with captopril.
Circulation 1985;72:406–12.
11. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with
symptomless left ventricular dysfunction after myocardial infarction. Lancet
1988;i:255–9.
12. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prog-
nostic importance of patency of the infarct-related coronary artery after
thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:
61–7.
13. Lamas GA, Flaker GC, Mitchell G, et al. for the Survival and Ventricular
Enlargement Investigators. Effect of infarct artery patency on prognosis after
acute myocardial infarction. Circulation 1995;92:1101–9.
14. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility
for thrombolytic therapy in acute myocardial infarction. Br Med J 1996;312:
1637–41.
15. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase
on left ventricular function and early survival after acute myocardial
infarction. N Engl J Med 1987;317:850–5.
16. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID).
Prevention of cardiovascular events and death with pravastatin in patients
coronary heart disease and a broad range of initial cholesterol levels. N Engl
J Med 1998;339:1349–57.
17. The GUSTO Angiographic Investigators. The effects of tissue plasmino-
gen activator, streptokinase, or both on coronary-artery patency, ventric-
ular function, and survival after acute myocardial infarction [published
erratum appears in N Engl J Med 1994;330:516]. N Engl J Med
1993;329:1615–22.
18. Gibson CM, Cannon CP, Daley WL, et al. for the TIMI 4 Study Group.
TIMI frame count: a quantitative method of assessing coronary artery flow.
Circulation 1996;93:879–88.
19. Cross DB, Ashton NG, Norris RM, White HD. Comparison of the effects of
streptokinase and tissue plasminogen activator on regional wall motion after
first myocardial infarction: analysis by the centerline method with correction
for area at risk. J Am Coll Cardiol 1991;17:1039–46.
20. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term
enalapril therapy on cardiac structure and function in patients with left
ventricular dysfunction: results of the SOLVD echocardiography substudy.
Circulation 1995;91:2573–81.
21. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early
prevention of left ventricular dysfunction after myocardial infarction with
angiotensin-converting-enzyme inhibition. Lancet 1991;337:872–6.
22. Pfeffer MA, Braunwald E, Moye´ LA, et al. on behalf of the SAVE
investigators. Effect of captopril on mortality and morbidity in patients with
left ventricular dysfunction after myocardial infarction: results of the survival
and ventricular enlargement trial. N Engl J Med 1992;327:669–77.
23. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimen-
tal infarct size by an angiotensin-converting enzyme inhibitor. Circulation
1982;65:40–8.
24. Taylor GJ, Humphries JO, Mellits ED, et al. Predictors of clinical course,
coronary anatomy and left ventricular function after recovery from acute
myocardial infarction. Circulation 1980;62:960–70.
25. Norris RM, Barnaby PF, Brandt PWT, et al. Prognosis after recovery from
first acute myocardial infarction: determinants of reinfarction and sudden
death. Am J Cardiol 1984;53:408–13.
26. Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF, Harris PJ. Infarct
artery perfusion and changes in left ventricular volume in the month after
acute myocardial infarction. J Am Coll Cardiol 1987;9:989–95.
27. Nijland F, Kamp O, Verheugt FWA, Veen G, Visser CA. Long-term
implications of reocclusion on left ventricular size and function after
successful thrombolysis for first anterior myocardial infarction. Circulation
1997;95:111–7.
28. White HD. Should all occluded infarct-related arteries be opened? [edito-
rial]. Eur Heart J 1997;18:1207–9.
29. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarc-
tion: experimental observations and clinical implications. Circulation 1990;
81:1161–72.
30. Oldroyd KG, Pye MP, Ray SG, et al. Effects of early captopril administration
on infarct expansion, left ventricular remodeling and exercise capacity after
acute myocardial infarction. Am J Cardiol 1991;68:713–8.
31. Foy SG, Crozier IG, Turner JG, et al. Comparison of enalapril versus
captopril on left ventricular function and survival three months after acute
myocardial infarction (the PRACTICAL study). Am J Cardiol 1994;73:
1180–6.
32. Pfeffer MA, Greaves SC, Arnold JMO, et al. for the Healing and Early
Afterload Reducing Therapy (HEART) Trial Investigators. Early versus
delayed angiotensin-converting enzyme inhibition therapy in acute myocar-
dial infarction: the Healing and Early Afterload Reducing Therapy Trial.
Circulation 1997;95:2643–51.
33. van Gilst WH, Kingma JH, Peels KH, Dambrink J-HE, St. John Sutton M,
on behalf of the CATS Investigators. Which patient benefits from early
angiotensin-converting enzyme inhibition after myocardial infarction? Re-
sults of one-year serial echocardiographic follow-up from the Captopril and
Thrombolysis Study (CATS). J Am Coll Cardiol 1996;28:114–21.
145JACC Vol. 33, No. 1 FRENCH ET AL.
January 1999:139–45 CAPTOPRIL DECREASES ANTERIOR REGIONAL WALL MOTION ABNORMALITIES
